GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Y-mAbs Therapeutics Inc (NAS:YMAB) » Definitions » Beneish M-Score
中文

Y-mAbs Therapeutics (Y-mAbs Therapeutics) Beneish M-Score

: -1.14 (As of Today)
View and export this data going back to 2018. Start your Free Trial

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Warning Sign:

Beneish M-Score -1.14 higher than -1.78, which implies that the company might have manipulated its financial results.

The historical rank and industry rank for Y-mAbs Therapeutics's Beneish M-Score or its related term are showing as below:

YMAB' s Beneish M-Score Range Over the Past 10 Years
Min: -2.22   Med: -1.91   Max: -1.14
Current: -1.14

During the past 8 years, the highest Beneish M-Score of Y-mAbs Therapeutics was -1.14. The lowest was -2.22. And the median was -1.91.


Y-mAbs Therapeutics Beneish M-Score Historical Data

The historical data trend for Y-mAbs Therapeutics's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Y-mAbs Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Beneish M-Score
Get a 7-Day Free Trial - - -2.22 -1.91 -1.14

Y-mAbs Therapeutics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.91 -1.66 -0.32 -0.70 -1.14

Competitive Comparison

For the Biotechnology subindustry, Y-mAbs Therapeutics's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Y-mAbs Therapeutics Beneish M-Score Distribution

For the Biotechnology industry and Healthcare sector, Y-mAbs Therapeutics's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Y-mAbs Therapeutics's Beneish M-Score falls into.



Y-mAbs Therapeutics Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Y-mAbs Therapeutics for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 1.3788+0.528 * 1.0216+0.404 * 1.9304+0.892 * 1.2996+0.115 * 0.8506
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 0.5664+4.679 * 0.045398-0.327 * 0.7826
=-1.14

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Dec23) TTM:Last Year (Dec22) TTM:
Total Receivables was $22.45 Mil.
Revenue was 23.363 + 20.454 + 20.751 + 20.251 = $84.82 Mil.
Gross Profit was 21.324 + 17.809 + 16.102 + 18.168 = $73.40 Mil.
Total Current Assets was $111.11 Mil.
Total Assets was $127.87 Mil.
Property, Plant and Equipment(Net PPE) was $1.64 Mil.
Depreciation, Depletion and Amortization(DDA) was $0.74 Mil.
Selling, General, & Admin. Expense(SGA) was $44.86 Mil.
Total Current Liabilities was $20.13 Mil.
Long-Term Debt & Capital Lease Obligation was $0.52 Mil.
Net Income was -0.988 + -7.747 + -6.302 + -6.39 = $-21.43 Mil.
Non Operating Income was 0 + 0 + 0 + 0 = $0.00 Mil.
Cash Flow from Operations was -8.036 + -1.338 + -4.734 + -13.124 = $-27.23 Mil.
Total Receivables was $12.53 Mil.
Revenue was 31.447 + 12.537 + 10.797 + 10.486 = $65.27 Mil.
Gross Profit was 29.427 + 10.062 + 9.557 + 8.655 = $57.70 Mil.
Total Current Assets was $130.45 Mil.
Total Assets was $141.46 Mil.
Property, Plant and Equipment(Net PPE) was $2.34 Mil.
Depreciation, Depletion and Amortization(DDA) was $0.84 Mil.
Selling, General, & Admin. Expense(SGA) was $60.94 Mil.
Total Current Liabilities was $28.28 Mil.
Long-Term Debt & Capital Lease Obligation was $0.90 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(22.454 / 84.819) / (12.531 / 65.267)
=0.264728 / 0.191996
=1.3788

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(57.701 / 65.267) / (73.403 / 84.819)
=0.884076 / 0.865408
=1.0216

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (111.111 + 1.636) / 127.869) / (1 - (130.447 + 2.343) / 141.456)
=0.118262 / 0.061263
=1.9304

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=84.819 / 65.267
=1.2996

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(0.839 / (0.839 + 2.343)) / (0.735 / (0.735 + 1.636))
=0.263671 / 0.309996
=0.8506

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(44.856 / 84.819) / (60.939 / 65.267)
=0.528844 / 0.933688
=0.5664

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((0.517 + 20.128) / 127.869) / ((0.899 + 28.284) / 141.456)
=0.161454 / 0.206304
=0.7826

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(-21.427 - 0 - -27.232) / 127.869
=0.045398

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Y-mAbs Therapeutics has a M-score of -1.14 signals that the company is likely to be a manipulator.


Y-mAbs Therapeutics Beneish M-Score Related Terms

Thank you for viewing the detailed overview of Y-mAbs Therapeutics's Beneish M-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Y-mAbs Therapeutics (Y-mAbs Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
230 Park Avenue, Suite 3350, New York, NY, USA, 10169
Y-mAbs Therapeutics Inc is a commercial-stage biopharmaceutical company. It is mainly engaged in the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer. DANYELZA, is the first FDA-approved product of the company which is a recombinant humanized immunoglobulin G, subtype 1k, or IgG1k, monoclonal antibody or mAb that targets ganglioside GD2, which is expressed in various neuroectoderm-derived tumors and sarcomas. The vast majority of the Company's product sales are generated in the United States with additional sales outside the United States in China and Israel through sublicenses and distribution agreements.
Executives
Thomas Gad director, officer: President and Chairman C/O Y-MABS THERAPEUTICS, INC., 230 PARK AVENUE, 33RD FLOOR, NEW YORK NY 10169
Biotech Aps Wg 10 percent owner RUNGSTED STRANDVEJ 113, RUNGSTED KYST G7 2960
Johan Wedell-wedellsborg director, 10 percent owner RUNGSTED STRANDVEJ 113, RUNGSTED KYST G7 2960
Michael J Rossi director, officer: President & CEO 230 PARK AVENUE, SUITE 3350, NEW YORK NY 10169
Vignesh Rajah officer: SVP and CMO HENRIKSHOJ 8, ROOM 4, VEDBAEK G7 DK-2950
Bo Kruse director, officer: EVP, CFO, Secy & Treas. C/O Y-MABS THERAPEUTICS, INC., 230 PARK AVENUE, 33RD FLOOR, NEW YORK NY 10169
Susan Laura Smith officer: Senior Vice President, CCO 5 OVERLOOK CT, LAMBERTVILLE NJ 08530
David N Gill director C/O NXSTAGE MEDICAL INC. (NXTM), 439 SOUTH UNION STREET, 5TH FLOOR, LAWRENCE MA 01843
Juan Moller San Pedro Claus director, officer: Chief Executive Officer C/O Y-MABS THERAPEUTICS, INC., 230 PARK AVENUE, SUITE 3500, NEW YORK NY 10169
Laura Hamill director 333 LAKESIDE DRIVE, FOSTER CITY CA 94404
Mahiuddin Ahmed officer: Sr. VP and CSO C/O Y-MABS THERAPEUTICS, INC., 230 PARK AVENUE, SUITE 3350, NEW YORK NY 10169
Philip Karl Herman officer: Sr. VP and CCO C/O Y-MABS THERAPEUTICS, INC., 230 PARK AVENUE, SUITE 3350, NEW YORK NY 10169
James Healy director 3000 SAND HILL ROAD, 4-250, MENLO PARK CA 94025
Gregory S Raskin director C/O MEMORIAL SLOAN KETTERING CANCER CENT, 1275 YORK AVENUE, BOX 524, NEW YORK NY 10065
Gerard Ber director C/O Y-MABS THERAPEUTICS, INC., 230 PARK AVENUE, 33RD FLOOR, NEW YORK NY 10169

Y-mAbs Therapeutics (Y-mAbs Therapeutics) Headlines